GSK

Haberler

Reuters - 23 saat önce

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

UPDATE 1-Pfizer wins bid to invalidate GSK's patents over RSV vaccine Adds background, reaction in paragraphs 3-5 LONDON, Oct 7 (Reuters) - Pfizer PFE.N on Monday won a bid in a London court to invalidate two of GSK's GSK.L patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults

Reuters - 23 saat önce

Pfizer wins bid to invalidate GSK's patents over RSV vaccine

Pfizer wins bid to invalidate GSK's patents over RSV vaccine LONDON, Oct 7 (Reuters) - Pfizer PFE.N on Monday won a bid in a London court to invalidate two of GSK's GSK.L patents relating to a respiratory syncytial virus (RSV) vaccine. The two pharmaceutical giants are among a number of companies in competition for a vaccine for RSV, which typically causes cold-like symptoms but is also a leading cause of pneumonia in toddlers and older adults.

Reuters - 4 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply

UPDATE 2-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply Adds new sourcing in paragraph 1, adds details throughout Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing . The move comes as a multi-state outbreak among livestock and poultry has caused human illnesses and infected more than 254 herds in 14 states since March,

Reuters - 4 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports Oct 4 (Reuters) - GSK GSK.L , Sanofi SASY.PA and CSL Ltd CSL.AX have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday. Reporting by Sriparna Roy in Bengaluru; Editing by Shreya Biswas

Reuters - 4 gün önce

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News

MEDIA-Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply- Bloomberg News -- Source link: https://tinyurl.com/4px3r67d -- Note: Reuters has not verified this story and does not vouch for its accuracy

Reuters - 5 gün önce

AstraZeneca, Danske Bank, Johnson Matthey

EUROPE RESEARCH ROUNDUP-AstraZeneca, Danske Bank, Johnson Matthey Oct 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Danske Bank and Johnson Matthey, on Thursday. HIGHLIGHTS * AstraZeneca AZN.L : Jefferies cuts target price to 11,400p from 11,700p * Baltic Classifieds Group Plc BCG.L : Berenberg raises target price to 360p from 300p * Danske Bank DANSKE.CO : JP Morgan cuts target price to DKK 185 from DKK 190 * John

Reuters - 1 hafta önce

WHO recommends maternal vaccine and antibody shot to prevent RSV in infants

UPDATE 1-WHO recommends maternal vaccine and antibody shot to prevent RSV in infants Adds comments from WHO press conference in paragraphs 7 to 10 By Kashish Tandon and Bhanvi Satija Oct 1 (Reuters) - The World Health Organization on Tuesday recommended vaccinating pregnant women and administering infants with an antibody to prevent severe respiratory synctial virus (RSV) infection in newborns.

Reuters - 1 hafta önce

WHO recommends maternal shot and antibody therapy to prevent RSV in infants

WHO recommends maternal shot and antibody therapy to prevent RSV in infants Oct 1 (Reuters) - The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory synctial virus (RSV) in infants. The recommendations, to administer both the shot and the antibody or either, come after the WHO's strategic advisory group on immunization met last week.

Reuters - 1 hafta önce

ASM International, Burberry, LVMH

EUROPE RESEARCH ROUNDUP-ASM International, Burberry, LVMH Oct 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including ASM International, Burberry and LVMH on Tuesday. HIGHLIGHTS * ASM International ASMI.AS : Stifel cuts target price to EUR 740 from EUR 800 * Burberry Group BRBY.L : HSBC raises target price to 770p from 690p * Carlsberg CARLb.CO : Jefferies cuts target price to DKK 1,000 from DKK 1,100 * LVMH LVMH.PA : HSBC raises target p

Reuters - 1 hafta önce

Pfizer to sell about $3.25 bln stake in Sensodyne-maker Haleon, bookrunner says

UPDATE 3-Drug giant Pfizer sells $3.3 bln stake in Sensodyne-maker Haleon Placing at a 3.3% discount to Haleon's last close Haleon to buy back 230 mln stg worth of shares from Pfizer Pfizer to remain top Haleon shareholder -LSEG data Updates dateline to Oct. 1, recasts with final pricing, shares, other details throughout By Shanima A Oct 1 (Reuters) - Pfizer PFE.N sold a stake in British consumer healthcare group Haleon HLN.L worth about $3.26 billion on Monday, cutting its shareholding in the m

Reuters - 2 hafta önce

Sensodyne maker Haleon to raise stake in China JV

UPDATE 2-Sensodyne maker Haleon to raise stake in China JV To buy additional 33% stake for $637 mln Will have option to buy out remaining 12% stake Deal 'strategically and commercially' compelling -CEO Recasts, adds detail, background By Yadarisa Shabong Sept 27 (Reuters) - Haleon HLN.L plans to increase its stake in its Chinese joint venture to 88% from 55%, the British consumer healthcare company said on Friday.

Reuters - 2 hafta önce

GSK Gets Positive EU Opinion For Liquid Menveo Vaccine

BRIEF-GSK Gets Positive EU Opinion For Liquid Menveo Vaccine Sept 24 (Reuters) - GSK plc GSK.L : POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE MARKETING AUTHORISATION IN EU EXPECTED BY NOVEMBER 2024 Source text for Eikon: ID:nRSX2993Fa Further company coverage: GSK.L

Reuters - 2 hafta önce

Biogen-UCB's lupus drug meets main goal of late-stage trial

CORRECTED-Biogen-UCB's lupus drug meets main goal of late-stage trial Corrects executive's name to Meyers from Myers in paragraphs 5 and 6 By Manas Mishra Sept 24 (Reuters) - Biogen BIIB.O and Belgian partner UCB UCB.BR said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed an earlier mid-stage study.

Reuters - 3 hafta önce

US FDA approves AstraZeneca's self-administered nasal spray flu vaccine

UPDATE 2-US FDA approves AstraZeneca's self-administered nasal spray flu vaccine Reworks lede, adds details on availability in paragraphs 4, details on the vaccine in paragraph 5, other vaccines in paragraph 9 Sept 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's AZN.L nasal spray flu vaccine for self-administration, making it the first of its kind.

Reuters - 3 hafta önce

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says

Coca-Cola plans to invest $1 billion in Nigeria operations, presidency says ABUJA, Sept 19 (Reuters) - Coca-Cola plans to invest $1 billion in its Nigeria operations over the next five years, the country's presidency said after a meeting between President Bola Tinubu and senior executives of the soft drinks maker on Thursday. Tinubu met John Murphy, president and chief financial officer of Coca‑Cola KO.N , Zoran Bogdanovic, CEO of Coca-Cola HBC CCH.L - one of Coca-Cola's many bottlers worldwid

Reuters - 3 hafta önce

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

UPDATE 1-Boehringer Ingelheim faces second hung jury in Chicago Zantac trial Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Updates Sept 18 story with statement from Boehringer Ingelheim in paragraph 5 By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as j

Reuters - 3 hafta önce

Boehringer Ingelheim faces second hung jury in Chicago Zantac trial

Reuters - 3 hafta önce

A second Zantac cancer trial ends with hung jury

A second Zantac cancer trial ends with hung jury Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns By Brendan Pierson Sept 18 (Reuters) - The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, as jurors in Chicago were unable to agree on whether Boehringer Ingelheim must pay damages to an Illinois man

Reuters - 3 hafta önce

GSK settles two California lawsuits related to heartburn drug Zantac

UPDATE 1-GSK settles two California lawsuits related to heartburn drug Zantac Adds background and context Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued heartburn drug Zantac caused cancer. GSK does not admit to any liability in either settlement, it said in a statement.

Reuters - 3 hafta önce

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

UPDATE 1-GSK's RSV, Shingles vaccines show on-par immune response in joint trial Adds details on study in paragraph 2, company's statement in paragraph 4 Sept 18 (Reuters) - British drugmaker GSK GSK.L said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.

Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

GSK

Haberler

Şartlar

Popüler varlıklar

XM canlı destek